Prosecution Insights
Last updated: November 04, 2026

Chengdu Zenitar Biomedical Technology Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Chengdu Zenitar Biomedical Technology Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The profile identifies 1 distinct examiner and 1 distinct art unit, so the pending matter is concentrated in one examination assignment.

MCMILLIAN, KARA RENITA is the busiest examiner, with 1 pending matter. That equals the portfolio's pending office actions and indicates that this examiner handles the full active docket represented here. The practical focus is a targeted review of the single matter, its technical record, and the examiner's applicable prosecution approach.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
MCMILLIAN, KARA RENITA 1 30.9% +37.9%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18579906 PREPARATION OF HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF MCMILLIAN, KARA RENITA —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18579906 PREPARATION OF HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF MCMILLIAN, KARA RENITA —

Top Art Units

Art UnitApps
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18579906 PREPARATION OF HISTONE DEACETYLASE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF MCMILLIAN, KARA RENITA 1623 §103§112Other Final Rejection — Pending Jan 17, 2024

Managing Chengdu Zenitar Biomedical Technology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Chengdu Zenitar Biomedical Technology Co. Ltd. have?

Chengdu Zenitar Biomedical Technology Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Chengdu Zenitar Biomedical Technology Co. Ltd. applications?

Kara Renita Mcmillian has the most, with 1 of Chengdu Zenitar Biomedical Technology Co. Ltd.'s pending office actions.

What technology area are Chengdu Zenitar Biomedical Technology Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month